Wire · opportunities
A Gene Therapy Aims to Do What Dry Macular Degeneration Drugs Cannot: Restore Sight
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 7 October 2026 · Fusion42 review
A novel gene therapy, sonpiretigene isteparvovec (son-vec), has shown promising early results in improving vision in patients with Stargardt disease and signals potential in treating geographic atrophy, a form of dry macular degeneration. The therapy uses optogenetics to reprogram surviving retinal cells to restore light sensitivity, leading to plans for a Phase 2 trial bypassing usual safety stages.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
You have a rare chance to enter the eye treatment market with gene therapies that restore vision, not just slow loss. The next wave of patient demand will come from therapies like son-vec that offer hope of recovery rather than management.
◆ Coverage
1 source · 6 Oct 2026
◆ Related on Wire
◆ Topics